Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what plans his Department has to (a) collect and (b) disseminate data on individual women who have been prescribed anti-epileptic drugs to enable investigation into the reasons for the teratogenicity of valproate and other epilepsy medication.

The Medicines and Healthcare products Regulatory Agency and NHS Digital have been working to build a Registry to monitor the use of valproate and compliance with the current regulatory position and to monitor any children born to women on valproate. The Registry is being built around routinely collected data on all women in England who are taking National Health Service-prescribed valproate and identifies when they are pregnant and accessing NHS care for that pregnancy. Work is now ongoing to extend the Registry to include women in the devolved administrations. The Registry will also be extended to include all girls and women prescribed an antiepileptic drug. This has been prioritised within the next phase of development. Once available, this data will be accessible to support additional research.